Image credit Johnson & Johnson (JNJ) has long been a company that has many cash demands. It pays a sizable dividend, buys back stock by the billion and is almost constantly acquiring competitors. Its FCF is prodigious to say …
Johnson & Johnson (NYSE: NYSE:JNJ) is a $358 billion company today. Investors that bought shares one year ago are sitting on a 10.56% total return. That's below the S&P 500's return of 16.05%. Johnson & Johnson stock is …
Johnson & Johnson (ticker: JNJ) has largely lied low in an otherwise contentious year for large name-brand U.S.-based companies. With big oil companies fighting falling prices, big auto and manufacturing firms answering to an "America …
Johnson & Johnson (NYSE:JNJ) is an old stalwart, known for being one of the most reliable stocks for dividend investors. It is among an elite class of companies that have increased their dividend payouts every year for at least 25 years. …
Johnson & Johnson (NYSE:JNJ)‘s stock had its “hold” rating reaffirmed by research analysts at Jefferies Group LLC in a research note issued to investors on Friday, July 14th. They presently have a $145.00 price target on the stock, up from …
Johnson & Johnson (NYSE: JNJ) stock first traded back in 1944. For the first 58 years of the company's existence, it was privately held by the Johnson family. J&J stock has been a big winner throughout the years, but never more so …
Linked here is a detailed quantitative analysis of Johnson & Johnson (JNJ). Below are some highlights from the above linked analysis: Company Description: Johnson & Johnson is a leader in the pharmaceutical, medical device and …
Related: Johnson & Johnson earnings: Expect a slow first quarter due to drug segment challenges and Johnson & Johnson’s stock falls after sales miss offsets profit beat and raised outlook But change could be on the horizon, as …